Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.

Ma J, Waxman DJ.

Clin Cancer Res. 2009 Jan 15;15(2):578-88. doi: 10.1158/1078-0432.CCR-08-1174.

PMID:
19147763
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Antiangiogenesis enhances intratumoral drug retention.

Ma J, Chen CS, Blute T, Waxman DJ.

Cancer Res. 2011 Apr 1;71(7):2675-85. doi: 10.1158/0008-5472.CAN-10-3242. Epub 2011 Mar 29.

PMID:
21447737
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.

Ma J, Waxman DJ.

Mol Cancer Ther. 2008 Jan;7(1):79-89. doi: 10.1158/1535-7163.MCT-07-0584.

PMID:
18202011
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.

Clin Cancer Res. 2008 Nov 15;14(22):7272-83. doi: 10.1158/1078-0432.CCR-08-0652.

PMID:
19010843
[PubMed - indexed for MEDLINE]
Free Article
5.

Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.

He Q, Gao J, Ge S, Wang T, Li Y, Peng Z, Li Y, Shen L.

J Cancer Res Clin Oncol. 2014 Sep;140(9):1575-83. doi: 10.1007/s00432-014-1693-4. Epub 2014 May 8.

PMID:
24804814
[PubMed - indexed for MEDLINE]
6.

Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.

Canu B, Fioravanti A, Orlandi P, Di Desidero T, Alì G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R, Bocci G.

Neoplasia. 2011 Mar;13(3):217-29.

PMID:
21390185
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.

Zhang K, Waxman DJ.

Mol Cancer Ther. 2013 May;12(5):787-98. doi: 10.1158/1535-7163.MCT-12-1240. Epub 2013 May 1.

PMID:
23635653
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS.

Cancer Res. 2002 May 15;62(10):2731-5.

PMID:
12019144
[PubMed - indexed for MEDLINE]
Free Article
10.

VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.

Doloff JC, Waxman DJ.

Cancer Res. 2012 Mar 1;72(5):1103-15. doi: 10.1158/0008-5472.CAN-11-3380. Epub 2012 Jan 11.

PMID:
22237627
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.

Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T.

Jpn J Clin Oncol. 2014 Jun;44(6):570-8. doi: 10.1093/jjco/hyu045. Epub 2014 Apr 21.

PMID:
24755544
[PubMed - indexed for MEDLINE]
Free Article
12.

Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.

Doloff JC, Khan N, Ma J, Demidenko E, Swartz HM, Jounaidi Y.

Curr Cancer Drug Targets. 2009 Sep;9(6):777-88.

PMID:
19754361
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

[Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft].

Zhao J, Zhao T, Xie F, He B.

Nan Fang Yi Ke Da Xue Xue Bao. 2012 Jun;32(6):890-3. Chinese.

PMID:
22699078
[PubMed - indexed for MEDLINE]
Free Article
14.

Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.

Manley E Jr, Waxman DJ.

J Pharmacol Exp Ther. 2013 Feb;344(2):368-77. doi: 10.1124/jpet.112.200089. Epub 2012 Nov 28.

PMID:
23192656
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.

Rössler J, Monnet Y, Farace F, Opolon P, Daudigeos-Dubus E, Bourredjem A, Vassal G, Geoerger B.

Int J Cancer. 2011 Jun 1;128(11):2748-58. doi: 10.1002/ijc.25611. Epub 2010 Oct 8.

PMID:
20715103
[PubMed - indexed for MEDLINE]
16.

Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.

Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U.

Invest New Drugs. 2014 Feb;32(1):47-59. doi: 10.1007/s10637-013-9974-3. Epub 2013 Jun 2.

PMID:
23728939
[PubMed - indexed for MEDLINE]
17.

Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.

Chen CS, Doloff JC, Waxman DJ.

Neoplasia. 2014 Jan;16(1):84-96.

PMID:
24563621
[PubMed - indexed for MEDLINE]
Free PMC Article
18.
19.
20.

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.

Anticancer Res. 2008 Nov-Dec;28(6A):3801-8.

PMID:
19189667
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk